Clinical Research

Clinical Research

Progenity conducts and publishes ongoing research, to encourage open sharing of ideas and information that can lead to better patient care.

Our ingestible technologies show promising results that could transform clinical diagnostics and therapeutics for GI disease. Read more about the difficulties in diagnosing GI disease and how our technology is an expected solution.

At Digestive Disease Week® 2019 in San Diego, we presented results from three proof-of-concept studies that represent potential breakthrough systems for diagnosing, treating, and monitoring digestive diseases through ingestible technologies.

Guidelines for identifying hemoglobinopathy carriers recommend genotyping only for certain patients. But these results show that concurrent testing may be the way to go.

Zoom in from full chromosome to single nucleotide with a new application for cell-free DNA (cfDNA) technology. Expand your patients’ prenatal options with the ResuraTM Prenatal Test.

Did you know maternal blood chimerism can be detected during cell-free DNA screening? Neither did we, until this happened.

This is the first study using primary data to uncover the economic burden of preeclampsia. Read to find out just how high the burden is on our healthcare system.

Sickle cell anemia (Hb S) is a classic study in carrier status and recessive inheritance, but the beta-hemoglobinopathies are far more complex than they seem. This study highlights the diversity within this group of disorders, and within the ethnicities at risk.

Know more. Learn how we have improved our Innatal® Prenatal Screen.

Not all carriers of alpha-thalassemia have the same disease transmission outcomes. Read more about how the ethnicity with the highest carrier frequency is not the ethnicity with the highest risk of having an affected child.

The association between fragile X premutations and primary ovarian insufficiency made us wonder. Now we know the answer is “Yes.”